KREMEN2 and non-small cell lung carcinoma: The results are shown in Fig. 1H and I, and indicate that NSCLC patients with high Kremen2 expression levels were associated with poorer overall survival (OS), as shown by a lower OS and first progression survival (P < 0.05).